Human Enhancement Technology for Military Medicine: Strengthening Resilience Through Dual-Use Innovation
| Reference number | |
| Coordinator | Interlinked AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2025 - August 2026 |
| Status | Ongoing |
| Venture | Civil-military synergies |
| Call | Acceleration of civil-military innovations by 2025 |
Purpose and goal
IV therapy is a vital part of both civilian healthcare and the care of wounded soldiers in combat. During transfer and evacuation, IV catheters are sometimes dislodged accidentally, causing interruption of treatment, need to insert a new catheter, risk of infection, and medication errors. In line with NATO´s priority technology area "Biotechnology and Human Enhancement Technologies", the project aims to strengthen survivability and continuity of care related to IV therapy.
Expected effects and result
The connector technology being evaluated in the project is a weak link with double valves. The two connector parts separate at a defined force and can quickly be reconnected, ensuring that the IV catheter is not dislodged, that medicine and fluids are not spilled, and continuous treatment. Results from the project include a defence-adapted verification dossier, pilot data from simulated CASEVAC/MEDEVAC, a Sweden-based supply chain plan and accelerator results (in line with DIANA/NIF).
Planned approach and implementation
During the project, we will adapt, verify and pilot test the ReLink safety connector for defence medicine and civil preparedness, including validation of the connector´s performance and workflow benefits under severe conditions. In addition, a plan for a dual-use market launch for Swedish and allied defence and emergency care systems will be developed.